Header Logo

Connection

CARL ALLEN to Proto-Oncogene Proteins B-raf

Back to Details
This is a "connection" page, showing publications CARL ALLEN has written about Proto-Oncogene Proteins B-raf.
CARL ALLEN
Connection Strength
3.018
Proto-Oncogene Proteins B-raf
  1. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.544
  2. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.491
  3. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023 12 12; 56(12):2790-2802.e6.
    View in: PubMed
    Score: 0.202
  4. Prevalence of the BRAFV600E mutation in Greek adults with Langerhans cell histiocytosis. Pediatr Hematol Oncol. 2022 Sep; 39(6):540-548.
    View in: PubMed
    Score: 0.178
  5. Langerhans cell histiocytosis: Version 2021. Hematol Oncol. 2021 Jun; 39 Suppl 1:15-23.
    View in: PubMed
    Score: 0.169
  6. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med. 2021 05; 27(5):851-861.
    View in: PubMed
    Score: 0.168
  7. Langerhans cell histiocytosis. Blood. 2020 04 16; 135(16):1319-1331.
    View in: PubMed
    Score: 0.156
  8. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.144
  9. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018 01 02; 215(1):319-336.
    View in: PubMed
    Score: 0.133
  10. New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Mol Cancer. 2017 07 06; 16(1):115.
    View in: PubMed
    Score: 0.129
  11. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
    View in: PubMed
    Score: 0.128
  12. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.126
  13. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. Hematology Am Soc Hematol Educ Program. 2015; 2015:559-64.
    View in: PubMed
    Score: 0.108
  14. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 06; 124(19):3007-15.
    View in: PubMed
    Score: 0.106
  15. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.103
  16. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.051
  17. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
    View in: PubMed
    Score: 0.051
  18. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.